Prosecution Insights
Last updated: November 04, 2026
Application No. 18/054,149

Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis

Non-Final OA §102§103§112
Filed
Nov 10, 2022
Priority
Nov 10, 2021 — provisional 63/277,615
Examiner
ROGERS, JAMES WILLIAM
Art Unit
1618
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Primo Biotechnology Co. Ltd.
OA Round
3 (Non-Final)
46%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
69%
With Interview

Examiner Intelligence

Grants 46% of resolved cases
46%
Career Allowance Rate
420 granted / 907 resolved
-13.7% vs TC avg
Strong +23% interview lift
Without
With
+22.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 10m
Avg Prosecution
49 currently pending
Career history
966
Total Applications
across all art units

Statute-Specific Performance

§101
0.7%
-39.3% vs TC avg
§103
42.5%
+2.5% vs TC avg
§102
22.2%
-17.8% vs TC avg
§112
23.9%
-16.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 907 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 7/13/ 2026 has been entered. Amendments Applicants amendments to the claims filed 7/13/2026 have been entered. Any objection\rejections from the previous office action filed 1/15/2026 not addressed below has been withdrawn. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 3 and 13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. In particular the examiner did not find support in the specification as originally filed for the new limitation that hepatic metastases are caused by spread of gastric cancer. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1,4,7 and 14 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Kesler et al. “68Ga-Labeled Prostate-Specific Membrane Antigen Is a Novel PET/CT Tracer for Imaging of Hepatocellular Carcinoma: A Prospective Pilot Study”, THE JOURNAL OF NUCLEAR MEDICINE • Vol. 60 • No. 2 • February 2019, for the reasons set forth in the previous office action filed 1/15/2026. Claim(s) 1,4,7 and 14 is/are rejected under 35 U.S.C. 102a1 as being anticipated by Dondi et al. “Radiolabelled PSMA PET/CT or PET/MRI in hepatocellular carcinoma (HCC): a systematic review”, Clinical and Translational Imaging (2020) 8:461–467, for the reasons set forth in the previous office action filed 1/15/2026. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1,4,7 and 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kesler et al., cited above, for the reasons set forth in the previous office action filed 1/15/2026. Claim(s) 1,4,7 and 14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dondi et al., cited above, for the reasons set forth in the previous office action filed 1/15/2026. Claim(s) 1,3-4,7 and 13-14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Kesler et al., cited above, in view of Gioia “Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase”, British Journal of Cancer (2015) 112, 809–818. Regarding claims 3 and 13, while Kesler teaches techniques for imaging hepatocellular carcinoma it is silent with respect to the cause of hepatic cancer from metastases of another cancer including breast cancer. Gioia is used primarily for its disclosure on early detection of metastatic disease in breast cancer patients with imaging, noting that in a patient liver metastasis was discovered 6 months in follow up imaging. See entire disclosure, especially abstract, Fig. 1 and 2, table 3. Since Kesler teaches imagining hepatocellular carcinoma using 68Ga-Labeled Prostate-Specific Membrane Antigen binding agents and Gioia teaches that breast cancer was well known to metathesize in the liver one of ordinary skill in the art would have a very high expectation of success in using the imaging agent of Kesler to diagnose hepatic metastases caused by breast cancer. Thus the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. “The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” KSR Int' l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007). Claim(s) 1,3-4,7 and 13-14 is/are rejected under 35 U.S.C. 103 as being unpatentable over Dondi et al., cited above, in view of Gioia, cited above. Regarding claims 3 and 13, while Dondi reviews radiolabeled PSMA binding agents, including 68Ga in PET/CT or PET/MRI imagining of HCC it is silent with respect to the cause of hepatic cancer from metastases of another cancer including breast cancer. Gioia is used primarily for its disclosure on early detection of metastatic disease in breast cancer patients with imaging, noting that in a patient liver metastasis was discovered 6 months in follow up imaging. See entire disclosure, especially abstract, Fig. 1 and 2, table 3. Since Dondi teaches imagining HCC using 68Ga-Labeled PSMA binding agents and Gioia teaches that breast cancer was well known to metathesize in the liver, one of ordinary skill in the art would have a very high expectation of success in using the imaging agents taught in Dondi to diagnose hepatic metastases caused by breast cancer. Thus the claimed invention would have been prima facie obvious since all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. “The combination of familiar elements according to known methods is likely to be obvious when it does no more than yield predictable results.” KSR Int' l Co. v. Teleflex Inc., 550 U.S. 398, 416 (2007). Response to Arguments Applicant's arguments filed 7/13/2026 have been fully considered but they are not persuasive. Applicants assert Kesler and Dondi are silent with respect to detecting hepatic metastases caused by spread of other cancers such as breast, pancreatic, colorectal and gastric. In response to applicant's argument that the references fail to show certain features of the invention, it is noted that the features upon which applicant relies (i.e., detecting hepatic metastases caused by spread of other cancers) are not recited in the rejected claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See In re Van Geuns, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). Note that only claims 3 and 13 feature such a limitation. As noted above claims 3 and 13 are considered obvious once the Gioia reference is considered. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to JAMES W ROGERS whose telephone number is (571)272-7838. The examiner can normally be reached 9:30-6:00 PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Michael Hartley can be reached at 571-272-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JAMES W ROGERS/Primary Examiner, Art Unit 1618
Read full office action

Prosecution Timeline

Nov 10, 2022
Application Filed
Jun 06, 2025
Non-Final Rejection mailed — §102, §103, §112
Dec 02, 2025
Response Filed
Jan 15, 2026
Final Rejection mailed — §102, §103, §112
Jul 13, 2026
Response after Non-Final Action
Jul 13, 2026
Request for Continued Examination
Sep 16, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779085
RADIOPAQUE POLYMERS
3y 3m to grant Granted Nov 03, 2026
Patent 12779054
LANTHANIDE COMPLEX FORMULATIONS
2y 3m to grant Granted Nov 03, 2026
Patent 12759047
Metal-based core nanoparticles, synthesis and use
4y 3m to grant Granted Oct 13, 2026
Patent 12758636
POLYTETRAFLUOROETHYLENE CO-POLYMER EMULSIONS
3y 6m to grant Granted Oct 13, 2026
Patent 12758658
DOUBLE-COMPONENT GASTRIC ULTRASOUND EXAMINATION AIDED DEVELOPER AND PREPARATION METHOD THEREFOR
2y 10m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
46%
Grant Probability
69%
With Interview (+22.6%)
3y 10m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 907 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month